Myokardia, Inc.

Elan Pharmaceuticals, Inc.

Danielle Aubele

Robert S McDowell

Yonghong Song

Johan D Oslob

Arvinder Sran

Marc Evanchik

Brian Kane

Jonathan Charles Fox

Robert G Anderson

Min Zhong

Hector Rodriguez

Simeon Bowers

Anh P Truong

Xiaocong Michael Ye

Puping Lu

Jae Kim

Dean R Artis

Yong-Liang Zhu

Roy K Hom

John P Anderson

R Jeffrey Neitz

Marc Adler

Jennifer Sealy

Robert Galemmo

Paul Beroza

Andrei William Konradi

Christopher Michael Semko

Darren B Dressen

Minghua Sun

Albert W Garofalo

Michael S Dappen

Gary D Probst

Mark Grillo

Raymond Ng

Pu-Ping Lu

Robert Mcdowell

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Pyrimidinedione compounds

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

4-methylsulfonyl-substituted piperidine urea compounds

The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

Bicyclic-pyrimidinedione compounds

The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

Cycloalkyl-substituted pyrimidinedione compounds

The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, E, E, R, R, Rand Rare defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Inhibitors of polo-like kinase

The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R, R, R, R, Rand Rare defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R, R, and Rare as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.

N-sulfonamido polycyclic pyrazolyl compounds

Growing community of inventors

San Mateo, CA, United States of America

Danielle Aubele